Health
Every year, women receive a breast cancer diagnosis and the first question they often ask is: could my daughter get this? It is a deeply human question, rooted in love, fear, and a desire to protect the people closest to us.
The word hereditary carries particular weight. It suggests inevitability. It suggests something written into us before we are born. But the science is considerably more layered than that, and most of what women hear about genetic breast cancer risk is either oversimplified or incomplete.
This editorial works through the evidence carefully, so that you can hold what is known, what is uncertain, and what the research genuinely does not yet answer.
Most women who develop breast cancer do not have a family history of the disease. Approximately 85 to 90 percent of breast cancer cases occur in women with no inherited gene mutation. This matters because the cultural narrative around breast cancer and family history has created a kind of false reassurance for women without a family history, while generating disproportionate anxiety in those who do have relatives with the disease.
Neither response is well-calibrated to the actual risk profile. What the evidence supports is a nuanced, individualised assessment, not a binary reading of family history.
“Most breast cancers, 87%, occur with no identifiable genetic mutation at all.”
BRCA1 and BRCA2 mutations significantly increase lifetime risk. BRCA1 carriers face a lifetime risk of approximately 65 to 72 percent; BRCA2 carriers approximately 45 to 69 percent. Researchers have now identified more than a dozen other genes, including PALB2, CHEK2, ATM, and BARD1, that confer elevated but more moderate risk.
Genetic testing has become more accessible, but access to informed genetic counseling has not kept pace. There is a risk that women receive results without adequate context, leading to either over-medicalisation or under-vigilance.
Women with first-degree relatives who have had breast cancer should discuss their risk profile with a clinician, not simply assume the worst or dismiss the relevance. The mental and emotional weight of uncertainty is significant. Evidence-based clarity, not false certainty in either direction, is the most useful thing medicine can offer women navigating this topic.
The science of hereditary breast cancer is more nuanced than the stories that circulate about it. Most breast cancers are not caused by inherited gene mutations. A family history does increase risk, meaningfully, but risk is not destiny, and the evidence points clearly to the value of early, informed, individualised assessment over blanket fear or blanket reassurance.
Women deserve access to this nuance, not a simplification that either dismisses their concern or amplifies it unnecessarily. That is what evidence-based editorial, translated carefully, exists to provide.